Trial Profile
A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg (Phase 3).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimasartan/hydrochlorothiazide (Primary) ; Fimasartan
- Indications Essential hypertension
- Focus Therapeutic Use
- 13 Jun 2013 Primary endpoint 'Diastolic-blood-pressure' has been met.
- 13 Jun 2013 Results presented at the 23rd European Meeting on Hypertension.
- 04 Jan 2012 Actual patient number (263) added as reported by ClinicalTrials.gov.